九典制药：签署小分子镇痛药物YJ2301项目的《专利及技术转让协议》

Core Viewpoint - JiuDian Pharmaceutical (300705.SZ) aims to enhance its product pipeline and market competitiveness in pain management by signing a patent and technology transfer agreement with Suzhou Yuanju Pharmaceutical Technology Co., Ltd. for the small molecule analgesic drug YJ2301, with a total transfer fee not exceeding RMB 400 million [1] Group 1 - The company held its 16th meeting of the 4th Board of Directors on December 11, 2025, to review and approve the agreement [1] - The agreement is part of the company's strategy to promote its transformation into innovative pharmaceuticals [1] - The collaboration is expected to strengthen the company's technical capabilities in the pain management sector [1]